Sernova Stock
Sernova Corp.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- Jonathan N. Rigby
- Employees
- 8
- Market cap
- $43 M
- IPO
- 29/04/1999
Sernova Corp. is a Canadian clinical-stage enterprise specializing in the development and commercialization of groundbreaking regenerative medicine therapies. Its core endeavors revolve around its proprietary Cell Pouch system and associated technologies, which encompass specialized therapeutic cells and mechanisms…
Sernova stock: price history
1D
+0.0%
1W
+0.0%
1M
+9.5%
6M
-37.8%
YTD
-11.5%
1Y
-32.4%
2Y
-57.4%
5Y
-91.0%
10Y
-57.4%
Next earnings date
Next earnings date
18/12/2026 (in 62 days)
Volatility around earnings
~37% weaker price swings than usual
Ask the agents about Sernova
Sernova stock metrics
P/E
-3.91
P/B
-3.69
EV/EBITDA
-5.1
RETURN ON EQUITY
21.5%
NET MARGIN
0.0%
DEBT/EQUITY
-0.22
DIVIDEND YIELD
0.0%
AS OF
31/07/2026
Free float & liquidity
FREE FLOAT
89.2%
FLOAT SHARES
336,770,260
AVG. DAILY VOLUME (30D)
355,812
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Sernova stock
What does Sernova do?
Sernova Corp. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is Jonathan N. Rigby, the company employs around 8 people.
The IPO was on 29/04/1999; the stock trades on TSX under the ticker SVA.TO.
When does Sernova report next?
The next earnings date is 18/12/2026.
Around past earnings, price swings were roughly -37% stronger than usual.
Does Sernova pay a dividend?
No, Sernova currently does not pay a dividend.
Which stocks are comparable to Sernova?
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Sernova stock analyzed?
Clicking "Analyze stock" lets five strategies assess Sernova against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.